Event Date
Wednesday, February 5th, 2020 – 12:00pm to 1:00pm
Speaker
Ron Schuchard, PhD, FARVO ERI Executive Director Envision, Inc.
Host
Dr. Fletcher
Abstract
Abstract - Recent FDA cleared/approved devices and biologics as well as current clinical trials in these types of products which promised improved vision by neurorecovery or at least slowing of the vision loss progression with neuroprotection including: 1) Spark Therapeutics LUXTURNA gene therapy; and 2) Okuvision OkuStim Electrical Stimulation Therapy. In addition, retinal and cortical prosthetics have promised restored vision by substituting mechanisms in the visual system. This presentation will provide a review of the actual results of these types of products and the challenges that would need to be overcome for these products to provide the promised improvement in vision.